



59th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE 2021 Online)

Online, September 22–26, 2021

Abstracts

Guest Editor

Mehul Dattani, London, UK

Programme Organising Committee

Nils Krone, Sheffield, UK, *Chair*

Mehul Dattani, London, UK, *President 2021*

Poonam Dharmaraj, Liverpool, UK, *Vice President 2021*

Stefano Cianfarini, Rome, Italy, *President-Elect*

Evangelia Charmandari, Athens, Greece, *Chair of Clinical Practice Committee*

Ola Nilsson, Örebro, Sweden, *Member*

Philippe Lysy, Brussels, Belgium, *Member*

Malgorzata Wasniewska, Messina, Italy, *Member*

Disclosure Statement Guest Editor

The guest editor does not have any conflicts of interest to declare.

This publication was sponsored by

Merck
Novo Nordisk
Pfizer
Sandoz

S. Karger
Medical and Scientific Publishers
Basel · Freiburg · Hartford · Oxford ·
Bangkok · Dubai · Kuala Lumpur ·
Melbourne · Mexico City · Moscow ·
New Delhi · Paris · Shanghai · Tokyo

Disclaimer

The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Drug Dosage

The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved.

No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center (see 'General Information').

© Copyright 2021 by S. Karger AG,
P.O. Box, CH-4009 Basel (Switzerland)
e-ISBN 978-3-318-07016-3

Contents

Plenary Lectures			
1	PL1	A Kiss before Sex	1
1	PL2	New Drugs for Youth with Type 2 Diabetes	2
2	PL3	Iodine Deficiency: A Public Health Issue	3
2	PL4	Development of Novel Therapies for Obesity	4
2	PL5	Advances and Challenges in the Care of Transgender/Gender Diverse Youth	5
2	PL6	The Current State of Epigenetic Research in Humans: Promise and Reality	6
2	PL7	Novel Insights into Weight Regulation	7
2	PL8	The Long Term Effects of Adolescent Obesity	8
Symposia			
3	S1	Endocrine Hypertension – Aetiology Directed Management	1.1–1.2
4	S2	Recent Breakthroughs in our Understanding of Calcium and Phosphate Homeostasis	2.1–2.2
4	S3	Management of Rare Obesity	3.1–3.2
5	S4	Recent Developments in Congenital Adrenal Hyperplasia	4.1–4.2
5	S5	Novel Therapies in Endocrinology	5.1–5.2
6	S6	Bone Formation: The Growth Plate and Beyond	6.1–6.2
6	S7	The Molecular Basis of Rare Endocrine Disorders	7.1–7.2
6	S8	Management of Childhood Brain Tumours	8.1–8.2
7	S9	Surgical Management of Endocrine Disorders	9.1–9.2
7	S10	Pathways to Improved Diagnosis and Management of Hypothalamo-Pituitary Disorders	10.1–10.2
8	S11	Calcium and Phosphate Beyond Bone	11.1–11.2
8	S12	Epigenetics and Genetics in Endocrine Disorders	12.1–12.2
9	S13	Joint ESPE/ISPAD Symposium: Novel Technologies in the Treatment of Diabetes	13.1–13.2
Meet the Expert			
10	MTE1	Thyroid Hormone Resistance Syndromes	1
10	MTE2	Diagnosis and Management of a Child with Pituitary Adenoma	2
10	MTE3	Management of a Child with Post-Neurosurgical Hyponatraemia	3
10	MTE4	Cystic Fibrosis-Related Diabetes	4
10	MTE5	Management of MEN1 in Children and Adolescents	5
10	MTE6	Autoimmune Endocrinopathy	6
11	MTE7	Endocrine and Osteoporosis Management of Boys with DMD	7
11	MTE8	Real-Life Diabetes Management during Exercise	8
How Do I...			
11	HDI1	How Do I... Session 1	1.1–1.3
11	HDI2	How Do I... Session 2	2.1–2.3

Controversies			
12	CON1	Should CGM be Used in Every Child with Diabetes?	1.1–1.2
12	CON2	Should Children with Isolated Idiopathic GHD be Retested in Early/Mid-Puberty, rather than Wait until Adult Height is Achieved?	2.1–2.2
GPED			
13	GPED	The Use of Long-Acting Insulin Analogues in Low and Middle Income Countries	1.1–1.2
Young Investigators			
14	YI	Young Investigators	1.1–1.5
Working Group Symposia			
15	WG1	ESPE Working Group on Bone and Growth Plate (BGP) Symposium	1.1–1.3
16	WG2	ESPE Working Group on Obesity (OWG) Symposium	2.1–2.2
16	WG3	ESPE Working Group on Diabetes Technology (DT) Symposium	3.1–3.3
17	WG4	ESPE Working Group on Disorders of Sex Development (DSD) Symposium	4.1–4.2
18	WG5	ESPE Working Group on Paediatric and Adolescent Gynaecology (PAG) Symposium	5.1–5.2
18	WG6	ESPE Working Group on Gender Incongruence (GI) Symposium	6.1–6.2
19	WG7	ESPE Working Group for Paediatric Endocrine Nurses (ESPEN) Symposium	7.1–7.3
19	WG8	ESPE Working Group on Turner Syndrome Symposium	8.1–8.3
Endo-ERN Symposium			
20	EE	Endo-ERN Symposium	1.1–1.3
ESPE Yearbook Sessions			
21	YB1	Year of Paediatric Endocrinology 1	1.1–1.5
22	YB2	Year of Paediatric Endocrinology 2	2.1–2.5
23	YB3	Year of Paediatric Endocrinology 3	3.1–3.5
Henning Andersen Prize Winners			
24	HA1	A Global Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP): 36-Month Outcomes in Participants Aged <25 Years	1
24	HA2	Biphasic Pattern of Circulating Reproductive Hormones in Female Infants – The Longitudinal COPENHAGEN Minipuberty Study	2
Free Communications			
25	FC1	Adrenal	1.1–1.6
30	FC2	Fat Metabolism and Obesity	2.1–2.6
33	FC3	Growth Disorders	3.1–3.6
36	FC4	Diabetes	4.1–4.6
40	FC5	Sex Development and Gender Incongruence	5.1–5.6
43	FC6	Bone and Mineral Metabolism	6.1–6.6
48	FC7	Fetal Endocrinology and Multisystem Disorders	7.1–7.6
52	FC8	Neuroendocrinology	8.1–8.6
56	FC9	Growth Hormone and IGFs	9.1–9.6
59	FC10	Thyroid	10.1–10.6
ePoster Presentations			
ePoster Category 1			
63	P1	Adrenal A	P1-1–P1-10
71	P1	Bone A	P1-11–P1-20
76	P1	Diabetes A	P1-21–P1-30
81	P1	Fat, Metabolism and Obesity A	P1-31–P1-40

86	P1	Sex Endocrinology and Gonads A	P1-41–P1-50
93	P1	Bone B	P1-51–P1-60
98	P1	Diabetes B	P1-61–P1-70
103	P1	Fetal Endocrinology and Multisystem Disorders A	P1-71–P1-80
108	P1	Pituitary A	P1-81–P1-90
114	P1	Thyroid A	P1-91–P1-100
120	P1	Adrenal B	P1-101–P1-110
125	P1	Fat, Metabolism and Obesity B	P1-111–P1-120
131	P1	Growth A	P1-121–P1-130
137	P1	Growth Hormone and IGFs A	P1-131–P1-140
143	P1	Sex Endocrinology and Gonads B	P1-141–P1-150
150	P1	Fetal Endocrinology and Multisystem Disorders B	P1-151–P1-160
155	P1	Growth B	P1-161–P1-170
161	P1	Growth Hormone and IGFs B	P1-171–P1-180
167	P1	Pituitary B	P1-181–P1-190
172	P1	Thyroid B	P1-191–P1-200
ePoster Category 2			
177	P2	Adrenals and HPA Axis	P2-1–P2-57
207	P2	Bone, Growth Plate and Mineral Metabolism	P2-58–P2-98
226	P2	Diabetes and Insulin	P2-99–P2-170
261	P2	Fat Metabolism and Obesity	P2-171–P2-229
292	P2	Fetal, Neonatal Endocrinology and Metabolism (to Include Hypoglycaemia)	P2-230–P2-245
300	P2	Growth Hormone and IGFs	P2-246–P2-276
317	P2	Growth and Syndromes (to Include Turner Syndrome)	P2-277–P2-332
346	P2	Multisystem Endocrine Disorders	P2-333–P2-345
351	P2	Pituitary, Neuroendocrinology and Puberty	P2-346–P2-393
375	P2	Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology	P2-394–P2-445
400	P2	Thyroid	P2-446–P2-491
424	Author Index		